Metabolic Disease Clinical Trial
Official title:
Effect of Large Neutral Amino Acids in Classical Phenylketonuria
This research investigates the effectiveness and safety of large neutral amino acid (LNAA) supplementation in patients with classical phenylketonuria (PKU). Advanced brain imaging techniques alongside comprehensive neuropsychological and functional assessments will be employed. Short-term and long-term follow-up of participants will be conducted.
Status | Not yet recruiting |
Enrollment | 30 |
Est. completion date | December 2027 |
Est. primary completion date | December 2026 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 16 Years to 50 Years |
Eligibility | Patients = 16 years of age with Classical PKU molecularly confirmed via the finding of two pathogenic variants in the phenylalanine hydroxylase (PAH) gene and/or historical evidence of Phe concentrations =1200 µmol/L in the medical history Inclusion Criteria: - Treatment initiation within the first month of life (ideally < 10 days of age) - Intelligence quotient (> 84) based upon the baseline neuropsychological evaluation - Conventional dietary treatment up to minimum 15 years of age - Written informed consent - Willing and able to comply with the protocol and study procedures Exclusion Criteria: - Unable or unwilling to adhere to the requirements of the study - A female who is pregnant or breastfeeding or planning to get pregnant during the study period - Concomitant medication that may interfere with the PET analysis, as judged by the investigator - A serious neuropsychiatric disease that could interfere with the subject's ability to participate in the study at the discretion of the investigator - Concomitant treatment with sapropterin (BH4) supplementation or Pegvaliase-pqpz (PALYNZIQ) - Failing to submit at least one blood Phe home sample during the year before study initiation - Standard MRI contraindications |
Country | Name | City | State |
---|---|---|---|
Denmark | Copenhagen University Hospital, Rigshospitalet | Copenhagen |
Lead Sponsor | Collaborator |
---|---|
Rigshospitalet, Denmark |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Fasting plasma amino acids, dried blood spots (finger-prick method) | Biomarkers such as the plasma Phe, Phe/Tyr ratio, Tyr/LNAA, Trp/LNAA ratio | Crossover trial 1: Baseline, at 1 and 9 weeks from baseline, or at 8 and 9 weeks from baseline; Crossover trial 2: Baseline, at 8 and 16 weeks from baseline; Extension study: at 4 months and 12 to 16 months from baseline | |
Other | Brain perfusion measures | Dynamic PET Imaging differences between groups and with intervention | Crossover trial 1: Baseline, at 1 and 9 weeks from baseline, or at 8 and 9 weeks from baseline; Crossover trial 2: Baseline, at 8 and 16 weeks from baseline; Extension study: at 4 months and 12 to 16 months from baseline | |
Other | Adherence to dietary treatment | 3-day diet record | Crossover trial 1: Baseline, at 1 and 9 weeks from baseline, or at 8 and 9 weeks from baseline; Crossover trial 2: Baseline, at 8 and 16 weeks from baseline; Extension study: at 4 months and 12 to 16 months from baseline | |
Other | Brain Magnetic Resonance Imaging (MRI) | Percent of patients with anatomic anomalies on MRI of the brain | Inclusion | |
Other | Wechsler Adult Intelligence Scale (WAIS) - IV | Baseline measure of cognitive ability, 40-160, highest is best | Inclusion | |
Primary | Dynamic positron emission tomography (PET) imaging with the fluorine-18-labeled tracer [18F]-(E)-N-(3-iodoprop-2-enyl)-2ß-carbofluoroethoxy-3ß-(4'-methyl phenyl)nortropane ([18F]FE-PE2I) | Change in specific binding ratio of dopamine transporter (DaT) with [18F]FE-PE2I | Crossover trial 1: at 1 and 9 weeks from baseline, or at 8 and 9 weeks from baseline Crossover trial 2: at 8 and 16 weeks from baseline Extension study: at 4 months and 12 to 16 months from baseline | |
Primary | Computerized neuropsychological testing (responses over study iPad) | Cambridge Neuropsychological Test Automated Assessment Battery (CANTAB) customized for study | Crossover trial 1: Baseline, at 1 and 9 weeks from baseline, or at 8 and 9 weeks from baseline; Crossover trial 2: Baseline, at 8 and 16 weeks from baseline; Extension study: at 4 months and 12 to 16 months from baseline | |
Secondary | Behaviour Rating Inventory of Executive Function - Adult version (BRIEF-A) | Patient-Reported Outcome Measure of executive functioning (ages 18 to 90), percentile, lowest is best | Crossover trial 1: Baseline, at 1 and 9 weeks from baseline, or at 8 and 9 weeks from baseline; Crossover trial 2: Baseline, at 8 and 16 weeks from baseline; Extension study: at 4 months and 12 to 16 months from baseline | |
Secondary | Behaviour Rating Inventory of Executive Function - Second edition (BRIEF-2) | Patient-Reported Outcome Measure of executive functioning (ages 11 to 18), percentile, lowest is best | Crossover trial 2: Baseline, at 8 and 16 weeks from baseline; Extension study: at 4 months and 12 to 16 months from baseline | |
Secondary | Adult attention deficit hyperactivity disorder (ADHD) Self-Report Scale (ASRS v1.1) | Patient-Reported Outcome Measure of attention in adults, 0-23, lowest is best | Crossover trial 1: Baseline, at 1 and 9 weeks from baseline, or at 8 and 9 weeks from baseline; Crossover trial 2: Baseline, at 8 and 16 weeks from baseline; Extension study: at 4 months and 12 to 16 months from baseline | |
Secondary | Adolescent ADHD Self-Report Scale | Patient-Reported Outcome Measure of attention in adolescents, 0-75, lowest is best | Crossover trial 2: Baseline, at 8 and 16 weeks from baseline; Extension study: at 4 months and 12 to 16 months from baseline | |
Secondary | PKU-QOL Questionnaire Adolescent or Adult version | Patient-Reported Outcome Measure of the impact of PKU and the PKU diet on quality of life | Crossover trial 1: Baseline, at 1 and 9 weeks from baseline, or at 8 and 9 weeks from baseline; Crossover trial 2: Baseline, at 8 and 16 weeks from baseline; Extension study: at 4 months and 12 to 16 months from baseline | |
Secondary | Symptom Checklist-90-Revised (SCL-90-R) | Patient-Reported Outcome Measure of psychopathological symptoms, percentile, lowest is best | Crossover trial 1: Baseline, at 1 and 9 weeks from baseline, or at 8 and 9 weeks from baseline; Crossover trial 2: Baseline, at 8 and 16 weeks from baseline; Extension study: at 4 months and 12 to 16 months from baseline | |
Secondary | Behavior Assessment System for Children, Third Edition (BASC-3) | Adolescent Self-Report form for measure of psychological general well-being, percentile, lowest is best | Crossover trial 2: Baseline, at 8 and 16 weeks from baseline; Extension study: at 4 months and 12 to 16 months from baseline | |
Secondary | Neuropsychological testing of flexibility and verbal fluency | Change in flexibility and verbal fluency using the Delis-Kaplan Executive Function System (D-KEFS) customized for study | Crossover trial 1: Baseline, at 1 and 9 weeks from baseline, or at 8 and 9 weeks from baseline; Crossover trial 2: Baseline, at 8 and 16 weeks from baseline; Extension study: at 4 months and 12 to 16 months from baseline | |
Secondary | Urine peripheral biomarkers of neurotransmitters | 6-sulfatoxymelatonin and dopamine | Crossover trial 1: Baseline, at 1 and 9 weeks from baseline, or at 8 and 9 weeks from baseline; Crossover trial 2: Baseline, at 8 and 16 weeks from baseline; Extension study: at 4 months and 12 to 16 months from baseline | |
Secondary | Incidence and severity of treatment-emergent adverse events (TEAEs) | Subjects with at least one TEAE or serious TEAE | Baseline to week 80 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06188728 -
Husk Fiber Intervention on Metabolic Health of Centrally Obese School Teachers
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05081037 -
Integrated Hyperglycaemia Incentivised Postnatal Surveillance Study (I-HIPS)
|
N/A | |
Recruiting |
NCT05318196 -
Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
|
||
Not yet recruiting |
NCT05461144 -
AI Models for Non-invasive Glycaemic Event Detection Using ECG in Type 1 Diabetics
|
||
Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A | |
Active, not recruiting |
NCT05505994 -
The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on Metformin
|
Phase 3 | |
Completed |
NCT03859934 -
Metabolic Effects of Melatonin Treatment
|
Phase 1 | |
Completed |
NCT03675360 -
Low-Carbohydrate Dietary Pattern on Glycemic Outcomes Trial
|
N/A | |
Recruiting |
NCT05711758 -
Efficacy and Safety of Endoscopic Antral Myotomy as a Novel Weight Loss Procedure
|
||
Recruiting |
NCT05112029 -
Metabolic Profile and Adipokine Levels in Young Hyperandrogenemic Females
|
||
Recruiting |
NCT03682640 -
Azithromycin Insulin Diet Intervention Trial in Type 1 Diabetes
|
Phase 2 | |
Completed |
NCT04854603 -
Dairy Products With Reduced Sugar and Blood Glucose
|
N/A | |
Recruiting |
NCT06024291 -
Reducing Circulating Sphingolipid Levels to Optimise Cardiometabolic Health - The SphingoFIT Trial
|
N/A | |
Recruiting |
NCT04904601 -
Freeze-dried Kale to Reduce Metabolic Risk in Saudi Subjects
|
N/A | |
Recruiting |
NCT04109586 -
Diet and Fat Mass After Traumatic Spinal Cord Injury
|
N/A | |
Recruiting |
NCT06009653 -
Effect of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With Obesity
|
Phase 4 | |
Completed |
NCT03067012 -
Nutritional Safety and Metabolic Benefits of Oncometabolic Surgery for Obese Gastric Cancer Patients
|
N/A | |
Recruiting |
NCT03309423 -
Is Venous to Arterial Conversion (v-TAC) of Blood Gas Reliable in Critical Ill Patients in the ICU?
|
N/A |